FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment ...
In April 2022, FDA approved axi-cel for adults with refractory or early relapsed LBCL, based on ZUMA-7 trial showing longer event-free survival vs standard therapy. Axi-cel had higher rates of cytokine release syndrome and neurologic toxicity but marks a paradigm shift in LBCL treatment.
Reference News
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment ...
In April 2022, FDA approved axi-cel for adults with refractory or early relapsed LBCL, based on ZUMA-7 trial showing longer event-free survival vs standard therapy. Axi-cel had higher rates of cytokine release syndrome and neurologic toxicity but marks a paradigm shift in LBCL treatment.